Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:activities |
gptkb:nucleoside_reverse_transcriptase_inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:1995
gptkb:FDA |
| gptkbp:brand |
gptkb:Epivir
|
| gptkbp:clinical_trial |
86%
|
| gptkbp:contraindication |
hypersensitivity to lamivudine
|
| gptkbp:developed_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:dosage_form |
gptkb:tablet
gptkb:item |
| https://www.w3.org/2000/01/rdf-schema#label |
3 TC
|
| gptkbp:ingredients |
C8 H10 N4 O3 S
|
| gptkbp:interacts_with |
gptkb:stavudine
gptkb:tenofovir gptkb:zidovudine |
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
J05 A F05
|
| gptkbp:is_used_for |
treatment of HIV
|
| gptkbp:name |
Essential Medicines
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea |
| gptkbp:bfsParent |
gptkb:lamivudine
|
| gptkbp:bfsLayer |
4
|